---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-216798"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:31:39.575382+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports Q2 2022 net income of $174.1M, cash runway through 2026 after Taiho deal

## Summary
- Cash and investments $656M as of June 30, 2022; expected to fund operations through 2026.
- Completed strategic collaboration with Taiho for CLN-081; received $275M upfront, eligible for $130M milestones.
- Net income of $174.1M in Q2 2022 vs net loss of $12.9M in Q1 2022, driven by $276.8M gain on sale of Cullinan Pearl.
- Updated CLN-081 data at ASCO: median DOR >21 months, median PFS 12 months, 41% confirmed ORR at 100mg BID.
- Initial clinical data for CLN-619 and CLN-049 expected by mid-2023; IND filings for CLN-617, CLN-978 in H1 2023.

## SEC filing metadata
- accession: 0001193125-22-216798
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522216798/0001193125-22-216798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522216798/d369450d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-216798
- JSON: https://secwatch.observer/filing/0001193125-22-216798.json
- Plain text: https://secwatch.observer/filing/0001193125-22-216798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.